MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026)

MoonLake Immunotherapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Operating Leases rose 56.3% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 56.3% YoY), while the FY2025 annual figure was $374000.0, down 74.35% from the prior year.
• Operating Leases for Q1 2026 stood at $1.8 million, up from $374000.0 in the prior quarter.
• The five-year high for Operating Leases was $3.7 million in Q1 2024, with the low at $13084.0 in Q3 2023.
• The 5-year median for Operating Leases is $1.3 million (2024), against an average of $1.4 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases jumped 14694.47% in 2024, then sank 74.89% in 2025.
• MoonLake Immunotherapeutics' Operating Leases stood at $128951.0 in 2022, then jumped by 1838.71% to $2.5 million in 2023, then slumped by 41.68% to $1.5 million in 2024, then sank by 74.35% to $374000.0 in 2025, then soared by 377.27% to $1.8 million in 2026.
• Business Quant data shows MLTX's Operating Leases at $1.8 million in Q1 2026, $374000.0 in Q4 2025, and $486000.0 in Q3 2025.